Cargando…

Tumor Drug Concentration and Phosphoproteomic Profiles After Two Weeks of Treatment With Sunitinib in Patients with Newly Diagnosed Glioblastoma

PURPOSE: Tyrosine kinase inhibitors (TKI) have poor efficacy in patients with glioblastoma (GBM). Here, we studied whether this is predominantly due to restricted blood–brain barrier penetration or more to biological characteristics of GBM. PATIENTS AND METHODS: Tumor drug concentrations of the TKI...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Linde, Myra E., Labots, Mariette, Brahm, Cyrillo G., Hovinga, Koos E., De Witt Hamer, Philip C., Honeywell, Richard J., de Goeij-de Haas, Richard, Henneman, Alex A., Knol, Jaco C., Peters, Godefridus J., Dekker, Henk, Piersma, Sander R., Pham, Thang V., Vandertop, William P., Jiménez, Connie R., Verheul, Henk M.W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Association for Cancer Research 2022
Materias:	Clinical Trials: Targeted Therapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9365363/ https://www.ncbi.nlm.nih.gov/pubmed/35165100 http://dx.doi.org/10.1158/1078-0432.CCR-21-1933

Ejemplares similares

Candidate biomarkers for treatment benefit from sunitinib in patients with advanced renal cell carcinoma using mass spectrometry-based (phospho)proteomics
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
por: Labots, Mariette, et al.
Publicado: (2020)

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
por: Beekhof, Robin, et al.
Publicado: (2019)

Phase I Dose-Escalation Study of Once Weekly or Once Every Two Weeks Administration of High-Dose Sunitinib in Patients With Refractory Solid Tumors
por: Rovithi, Maria, et al.
Publicado: (2019)

Acquired tumor cell resistance to sunitinib causes resistance in a HT-29 human colon cancer xenograft mouse model without affecting sunitinib biodistribution or the tumor microvasculature
por: Gotink, Kristy J., et al.
Publicado: (2014)

Alternative scheduling of pulsatile, high dose sunitinib efficiently suppresses tumor growth
por: Rovithi, Maria, et al.
Publicado: (2016)

Cross-resistance to clinically used tyrosine kinase inhibitors sunitinib, sorafenib and pazopanib
por: Gotink, Kristy J., et al.
Publicado: (2015)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Advancing wide implementation of precision oncology: A liquid nitrogen‐free snap freezer preserves molecular profiles of biological samples
por: van der Wijngaart, Hanneke, et al.
Publicado: (2023)

Phosphoproteomic Analysis of FLCN Inactivation Highlights Differential Kinase Pathways and Regulatory TFEB Phosphoserines
por: Glykofridis, Iris E., et al.
Publicado: (2022)

Time dependent effect of cold ischemia on the phosphoproteome and protein kinase activity in fresh-frozen colorectal cancer tissue obtained from patients
por: Buffart, Tineke E., et al.
Publicado: (2021)

The Potential Role of Lysosomal Sequestration in Sunitinib Resistance of Renal Cell Cancer
por: Azijli, Kaamar, et al.
Publicado: (2015)

Peptide-mediated ‘miniprep’ isolation of extracellular vesicles is suitable for high-throughput proteomics
por: Knol, Jaco C., et al.
Publicado: (2016)

Evaluation of potential circulating biomarkers for prediction of response to chemoradiation in patients with glioblastoma
por: van Linde, Myra E., et al.
Publicado: (2016)

Harnessing immunometabolism for cardiovascular health and cancer therapy
por: Markovska, Angela, et al.
Publicado: (2021)

Optimal treatment scheduling of ionizing radiation and sunitinib improves the antitumor activity and allows dose reduction
por: Kleibeuker, Esther A, et al.
Publicado: (2015)

Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies
por: Cordo’, Valentina, et al.
Publicado: (2022)

The Current Status of Immune Checkpoint Inhibitors in Neuro-Oncology: A Systematic Review
por: Brahm, Cyrillo G., et al.
Publicado: (2020)

Proteomic Analysis of miR-195 and miR-497 Replacement Reveals Potential Candidates that Increase Sensitivity to Oxaliplatin in MSI/P53wt Colorectal Cancer Cells
por: Poel, Dennis, et al.
Publicado: (2019)

Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3–Linked Sialic Acid Ligand Binding
por: Li, Rui-Jún Eveline, et al.
Publicado: (2021)

Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes
por: Coker, Elizabeth A., et al.
Publicado: (2022)

Effects of Cancer Presence and Therapy on the Platelet Proteome
por: Walraven, Maudy, et al.
Publicado: (2021)

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors
por: Cucchi, David G. J., et al.
Publicado: (2021)

Platelet function is disturbed by the angiogenesis inhibitors sunitinib and sorafenib, but unaffected by bevacizumab
por: Walraven, Maudy, et al.
Publicado: (2018)

Indirect Decompression Failure After Lateral Lumbar Interbody Fusion—Reported Failures and Predictive Factors: Systematic Review
por: Kirnaz, Sertac, et al.
Publicado: (2020)

High-Dose Intermittent Treatment with the Multikinase Inhibitor Sunitinib Leads to High Intra-Tumor Drug Exposure in Patients with Advanced Solid Tumors
por: Gerritse, Sophie L., et al.
Publicado: (2022)

Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126
por: Adema, Auke D., et al.
Publicado: (2011)

Randomized Phase II Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma
por: Nguyen, James, et al.
Publicado: (2023)

Combining radiotherapy with sunitinib: lessons (to be) learned
por: Kleibeuker, Esther A., et al.
Publicado: (2015)

Treatment outcome of patients with recurrent glioblastoma multiforme: a retrospective multicenter analysis
por: van Linde, Myra E., et al.
Publicado: (2017)

Data-driven prioritization and preclinical evaluation of therapeutic targets in glioblastoma
por: Brahm, Cyrillo G, et al.
Publicado: (2020)

Why and how to use virtual reality to study human social interaction: The challenges of exploring a new research landscape
por: Pan, Xueni, et al.
Publicado: (2018)

Selection of Protein Kinase Inhibitors Based on Tumor Tissue Kinase Activity Profiles in Patients with Refractory Solid Malignancies: An Interventional Molecular Profiling Study
por: Labots, Mariette, et al.
Publicado: (2018)

Evaluation of a tyrosine kinase peptide microarray for tyrosine kinase inhibitor therapy selection in cancer
por: Labots, Mariette, et al.
Publicado: (2016)

Phosphoproteomic Analysis Identifies TYRO3 as a Mediator of Sunitinib Resistance in Metastatic Thymomas
por: Küffer, Stefan, et al.
Publicado: (2022)

Transporter and Lysosomal Mediated (Multi)drug Resistance to Tyrosine Kinase Inhibitors and Potential Strategies to Overcome Resistance
por: de Klerk, Daniel J., et al.
Publicado: (2018)

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
por: van Beijnum, Judy R., et al.
Publicado: (2020)

Mind Perception Is the Essence of Morality
por: Gray, Kurt, et al.
Publicado: (2012)

Neuroethics: A New Way of Doing Ethics
por: Levy, Neil
Publicado: (2011)

A Life Worth Giving? The Threshold for Permissible Withdrawal of Life Support From Disabled Newborn Infants
por: Wilkinson, Dominic James
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ti6k57c25dvu48goeqcnnvmal5